P.P.W. Luke, C.A. O'Brien, A.M. Jevnikar and R. Zhong Pages 533 - 543 ( 11 )
Currently, lifelong immunosuppression is required for organ transplant recipients. The majority of transplant recipients will eventually develop chronic rejection with resultant graft loss, despite treatment with powerful immunosuppressive agents. These agents are also associated with numerous toxicities including reduced immunity against infection and malignancy. Therefore, the central goal in transplant science is to devise tolerance strategies in an attempt to establish a state of prolonged non-reactivity against the allograft, accompanied with preservation of an intact immune system. Although predictable tolerance induction has been elusive, we found that short course of the novel immunomodulatory agent, anti-CD45RB monoclonal antibody, leads to indefinite acceptance of renal allografts in mice, and has been shown to markedly prolong allograft survival in primates. We review the current state of development of this antibody, and the progress made in defining its mechanism of action., Anti-CD45RB, Monoclonal, Antibody-Mediated, Transplantation, Tolerance
Department of Surgery, London Health Sciences Centre, University Campus, P.O. Box 5339, London, Ontario, Canada, N6A 5A5.